The SpyGlass
BIM-IOL System
Two diseases.
One procedure. Enduring vision.
The SpyGlass BIM-IOL System* is designed to integrate lasting delivery of glaucoma medication into an innovative intraocular lens (IOL). Implanted during routine cataract surgery, the BIM-IOL System can potentially enable long-term intraocular pressure (IOP) control while restoring clear vision—addressing two leading causes of vision loss in a single procedure for potentially millions of patients.1-3
*The BIM-IOL System is not approved by the FDA and is under clinical development.
CEO Patrick Mooney
walks through
the BIM-IOL System
How it works
Dual drug-eluting pads:
Two non-bioerodible drug pads attach to the optic-haptic junction, locking into place and releasing bimatoprost directly into the aqueous humor.1
Integrated IOL system:
Our proprietary monofocal IOL has, in preliminary clinical trial results, demonstrated visual acuity improvements comparable to a commercially available monofocal IOL, while housing our proprietary bimatoprost delivery system.4
Routine insertion:
Our BIM-IOL System is loaded into an injector and inserted into the capsular bag as part of routine cataract surgery.1
Sustained drug delivery:
Positioned outside the visual axis, the pads are designed to provide sustained drug release over 3 years while maintaining clear optics.1,4
Expanding access to glaucoma treatment
no specialized techniques
or training, and is designed
to allow
100% of cataract
surgeons to treat 2
conditions—OAG/OHT and
cataracts—at the same time.1
33%
+
67%
Only 33% of cataract surgeons routinely* perform MIGS to reduce IOP for their glaucoma patients.5
The BIM-IOL System is designed to allow the remaining 67% of cataract surgeons to treat elevated IOP when performing routine cataract procedures.1
*At least twice per month.
Clinical results to date
The BIM-IOL System has shown consistent, long-term IOP reduction and drop-free outcomes, with visual improvements comparable to a commercially available IOL.
| First-in-Human Study at 36 Months4 | Phase 1/2 Study at 3 Months4 |
|---|---|
| Mean sustained IOP reduction of 37% | Mean IOP reduction of 36–37% |
| 95% of patients off topical drops | 97% of patients off topical drops |
| 100% of patients with BCDVA ≥20/30 | 100% of patients with BCDVA ≥20/40 and mean BCDVA of 20/20 |
| First-in-Human Study at 36 Months4 |
|---|
| Mean sustained IOP reduction of 37% |
| 95% of patients off topical drops |
| 100% of patients with BCDVA ≥20/30 |
| Phase 1/2 Study at 3 Months4 |
|---|
| Mean IOP reduction of 36–37% |
| 97% of patients off topical drops |
| 100% of patients with BCDVA ≥20/40 and mean BCDVA of 20/20 |
Potential for lasting performance
A single streamlined solution for cataracts and glaucoma designed to:
- Eliminate daily drop burden through sustained bimatoprost delivery4
- Simplify disease management for eye care professionals and patients4
- Preserve vision in the long term through sustained, localized drug delivery4
